- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01605513
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease (PEG-IFN-SA)
Phase I Clinical Trial of PEG-IFN-SA in HCV Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity
Panoramica dello studio
Descrizione dettagliata
Chronic infection with the hepatitis C virus (HCV) is a significant public health problem in china. Progressive liver disease, as a result of chronic HCV infection, usually develops slowly over 20-50 years and may lead to cirrhosis, hepatocellular carcinoma, liver failure and eventual death. Symptoms are typically mild and non-specific but nevertheless can cause a decrease in quality of life. Peginterferon alfa and ribavirin combination therapy is currently used in the china for treatment of chronic HCV. Successful treatment is considered to be attainment of a sustained virological response (SVR), defined as undetectable serum HCV ribonucleic acid (RNA) 6 months after cessation of treatment.
PEG-IFN-SA is a new recombinant interferon variant. Its N-terminus is modified by 20KD molecular weight single-methoxy polyethylene glycol (PEG). It consists of 171 amino acids before modification. PEG-IFN-SA is reorganization, unnatural existence and a new type of interferon (171Arg126Asp171IFN) after modification. The safety, tolerance and antiviral activity of PEG-IFN-SA was tested in adults with HCV infection.
PEG-IFN-SA was injected subcutaneously one times per week for 12 times. Peginterferon alfa-2a (Pegasys) is the positive control drug. 80 patients were randomly assigned to eight groups (PEG-IFN-SA 1.0μg/kg, Peginterferon alfa-2a 180 μg, PEG-IFN-SA 1.5 μg/kg,PEG-IFN-SA 2 μg/kg, PEG-IFN-SA 3 μg/kg,PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group,Intergen 15μg/48hours for 7 times and ribavirin 0.45g/bid for 10 times).
Clinical and biological adverse effects were recorded every week such as headache, nausea and vomiting. HCV RNA level was tested by COBAS Taqman HCV Test system of Roche. Blood cell counts were tested using an automatic cell counter such as WBC, neutrophil, PLT and HGB. Biochemical indicators were tested by automatic biochemical analysis instrument.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Jilin
-
Changchun, Jilin, Cina, 13021
- Phase One Clinical Trial ward, First Hospital, Jilin University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- enrolled voluntarily, can understand and sign informed consent;
- More than 18 years and less than 65 years;
- body mass index (BMI) is at 18 - 26;
- anti-HCV antibodies and / or HCV RNA positive, and / or other evidence of chronic hepatitis C;
- HCV RNA level ≥ 2000IU/ml (or equal to this viral load);
- Women's urine pregnancy test was negative, and the subjects (male subjects) is willing to have no pregnancy plans at next 18 months. (7) ALT is within 6 times of the upper limit of normal
Exclusion Criteria:
- pregnant women, lactating women or plan to pregnant the next 18 months.
- mental disorder, including history of mental illness (especially the history of depression or depressive tendencies, epilepsy, etc.);
- The patient who received interferon therapy within the past six months or had no response at previous interferon therapy.
- The patient who used a strong immune regulator over two weeks with three months before screening, such as adrenocorticotropic hormone, thymosin of α1, thymus 5 peptide.
- The patient who used hepatotoxic drugs with 6 months before screening, such as dapsone, erythromycin, fluconazole, ketoconazole, rifampin.
- co-infection with other viruses (HAV, HBV, HEV, the HIV, EBV, CMV) .
- patients with a history of hepatocellular carcinoma (HCC), or may had hepatocellular carcinoma evidence, such as imaging of suspicious nodules, or AFP abnormal (AFP> 200ng/mL). FibroScan value greater than or equal to F3 at Screening
- other causes of liver disease: a chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease, nonalcoholic steatohepatitis.
- autoimmune diseases, including psoriasis, systemic lupus erythematosus, thrombocytopenic purpura, and so on.
- heart and vascular system diseases, a history of myocarditis, hypertension, coronary heart disease, pathological arrhythmia, stroke.
- endocrine system diseases, including thyroid disease, diabetes, etc.
- pulmonary diseases, including invasive pulmonary disease, pneumonia, shortness of breath.
- Eye diseases, including retinopathy, retinopathy.
- chronic infectious disease history (history of tuberculosis).
- chronic kidney disease, serum creatinine level> 1.5 times upper limit of normal at screening, renal insufficiency, renal anemia history.
- anemia (including thalassemia, sickle hemoglobin, anemia), and hemophilia.
- peptic ulcer not controlled, colitis, pancreatitis and others.
- malignancies.
- peripheral blood checking: white blood cell count <3 × 109 / L; neutrophil count <1.5 x 109 / L; platelet count <90 × 109 / L; hemoglobin was less than the normal reference limit.
- serum total bilirubin> 2 times normal maximum reference value (ULN); serum albumin <35g / L; a history of decompensated cirrhosis evidence.
- evidence of drug addiction (including excessive alcohol intake, average alcohol consumption: men> 40g / day; women> 20g / day, equivalent to 50 degrees white wine 100ml / day and 50ml / day) within one year before screening.
- a serious history of drug and food allergy, especially towards the test drug (interferon, ribavirin).
- plans to accept an organ transplant or have organ transplant.
- participated other clinical trials before 3 months at screening
- The researchers judged the patients have other factors which may influence the experiment.
ribavirin exclusion criteria:
- women Hgb <12g/dl or men Hgb <13gdl at screening.
- anemia patients (eg, thalassemia, spherocytosis hyperlipidemia, gastrointestinal bleeding history) or suspected anemia patients.
- patients have a history of coronary artery disease or patients with cerebrovascular disease should not join this study, hemoglobin decline up to 4g/dl (it may be observed in the ribavirin treatment).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: recombinant interferon
PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
|
PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
The proportions of absence of detectable HCV RNA after the 12th treatment
Lasso di tempo: 12th week
|
12th week
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The proportions of absence of detectable HCV RNA after the 4th and 8th treatment
Lasso di tempo: 4th and 8th week
|
4th and 8th week
|
|
HCV RNA levels after the 4th, 8th and 12th treatment
Lasso di tempo: the 4th, 8th and 12th week
|
the 4th, 8th and 12th week
|
|
The test of Liver function
Lasso di tempo: the 2th, 4th, 6th, 8th,10th and 12th week
|
Liver function test:TBIL,IBIL, ALT, AST;
|
the 2th, 4th, 6th, 8th,10th and 12th week
|
The test of Kidney function
Lasso di tempo: the 2th, 4th, 6th, 8th,10th and 12th week
|
Kidney function test:BUN, CR;
|
the 2th, 4th, 6th, 8th,10th and 12th week
|
The test of Peripheral blood
Lasso di tempo: the 2th, 4th, 6th, 8th,10th and 12th week
|
Peripheral blood detection:WBC, RBC, HgB,PLT, neutrophil
|
the 2th, 4th, 6th, 8th,10th and 12th week
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: yanhua ding, associate professor, First Hospital, Jilin University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2011L0901
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Virus dell'epatite C
-
National Institute of Allergy and Infectious Diseases...CompletatoSano | Infezione da virus di Epstein BarrStati Uniti
-
TakedaCompletatoInfezioni da Flavivirus | Partecipanti sani | Virus, Zika | Malattia da virus ZikaStati Uniti, Porto Rico
-
Institute of Tropical Medicine, BelgiumCompletatoTrasmissione | Zik Virus | Malattia da virus Zika | Diffusione di virusBelgio
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaReclutamento
-
AlloVirAttivo, non reclutanteBK Infezione da virus | Infezioni da virus di Epstein-Barr | Infezioni da citomegalovirus | Infezione da adenovirus | Infezione da virus JC | Infezione da virus dell'herpes umano-6Stati Uniti
-
AlloVirTerminatoBK Infezione da virus | Infezioni da virus di Epstein-Barr | Infezioni da citomegalovirus | Infezione da adenovirus | Infezione da virus JC | Infezione da virus dell'herpes umano-6Corea, Repubblica di, Stati Uniti, Spagna, Francia, Tacchino, Australia, Regno Unito, Italia, Canada, Belgio
-
The University of Texas Medical Branch, GalvestonShriners Hospitals for ChildrenCompletatoBrucia | Varicella | Citomegalovirus | Virus dell'herpes simplex | Virus varicella-zoster | Virus dell'herpes umano
-
Merck Sharp & Dohme LLCCompletatoInfezione da virus della varicella
-
Universitair Ziekenhuis BrusselReclutamento
-
Marmara UniversityCompletatoComportamento sanitario | Papilloma-virus umanoTacchino
Prove cliniche su interferon
-
University of Colorado, DenverCompletato
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)CompletatoTubercolosi | Complesso correlato all'AIDSStati Uniti, Sud Africa
-
AOP Orphan Pharmaceuticals AGPharmaEssentia Corporation (Co-Sponsor for USA)CompletatoPolicitemia veraAustria, Bulgaria, Repubblica Ceca, Francia, Ungheria, Polonia, Slovacchia, Ucraina
-
Minneapolis Veterans Affairs Medical CenterUS Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... e altri collaboratoriCompletatoEpatite cronica C
-
M.D. Anderson Cancer CenterSchering-PloughCompletatoLeucemia mieloide cronicaStati Uniti
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.CompletatoRecettore per gli estrogeni negativo | HER2/Neu negativo | Recettore del progesterone negativo | Cancro al seno triplo negativo | Cancro al seno in stadio anatomico IV AJCCStati Uniti